Here is the synopsis of our sample research paper on THE PFIZER/PHARMACIA MERGER. Have the paper e-mailed to you 24/7/365.
Essay / Research Paper Abstract
This 4-page paper analyzes the merger between pharmaceutical companies Pfizer and Pharmacia from an accounting and product standpoint. Issues discussed include revenues and whether the acquisition has been successful. Bibliography lists 6 sources.
Page Count:
4 pages (~225 words per page)
File: D0_MTpfipha.rtf
Buy This Term Paper »
Unformatted sample text from the term paper:
the latter part of 2000, when powerhouse Pfizer, Inc. acquired rival Pharmacia. Because of this merger, Pfizer now has 14 drugs that are top sellers in their particular categories (Hoovers
Company Profiles, 2003). What we will try to show in this paper is that the merger has been extremely beneficial for Pfizer.
First, this is an interesting merger because it comes during a time in which the economy in general is in a downturn. As we mentioned before, the industry itself has
lightened up on mergers and acquisitions (Van Arnum, 2003). Although the pharmaceutical industry has not been impacted (although the industry is not
recession-proof, people will always need to buy drugs), things had been slowing up somewhat. Then Pfizer purchased Pharmacia, which has made the company the worlds largest research-based pharmaceutical company (Hoovers
Company Profiles, 2003). In addition to adding to Pfizers on-market drugs, the merger had also meant that Pfizers pipeline has a boost
- the company, thanks to the merger, has more than 200 projects in development including drugs for atherosclerosis, diabetes, osteoporosis, breast cancer, neuropathic pain, epilepsy, anxiety disorders, and Parkinsons Disease
(Hoovers Company Profiles, 2003) - all of which are considered diseases of concern by many Pfizer customers. In the respect of boosting
Pfizers product line, the merger has been extraordinarily successful. Additionally, the combined $7 billion research budget that this merger has yielded means that Pfizer will end up less dependent on
any one particular product (Brull et al, 2003). The merger has also made Pfizer 50 percent larger than its nearest competitor, GlaxoSmithKline
...